ClinicalTrials.gg
CompletedNCT02590653CONTRASTUpdated Mar 24, 2020

Assessment of the Effects of Atorvastatin Therapy on Myocardial Deformation Characteristics, in Patients With STEMI

A Phase 4 interventional study of Atorvastatin in Myocardial Infarction, sponsored by Penza State University. Completed at 1 site in Russian Federation. Open to participants aged 35 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-03-24.

Primary conditionST Elevation Myocardial InfarctionRegistry: Myocardial InfarctionReclassifiedWhy we changed it
Registry
Myocardial Infarction — the first condition term the registry derived for this study.
ClinicalTrials.gg
ST Elevation Myocardial Infarction
Why
  1. The study's title name ST Elevation Myocardial Infarction, a narrower term within Myocardial Infarction.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Penza State University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Oct 2014, registered Oct 2015).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
35 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in ST Elevation Myocardial Infarction with a site in Russian Federation — 1 open to participants now, 2 under way, none of them phase 3. ST Elevation Myocardial Infarction · Russian Federation.

Enrollment
7th of 10
200 · median 447
Started
2014
with 2 others
Phase 4
3 of 13
1 open now
Registered
8th of 13
by date
Lead sponsor
3 of 13
Penza State University

Among the 13 studies in ST Elevation Myocardial Infarction with a site in Russian Federation, this one is the 7th largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2014, is one of 3 in phase 4, and was the 8th registered.

ST Elevation Myocardial Infarction

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.

Browse ST Elevation Myocardial Infarction studies →

Open to participants now

1 of the 13 studies in ST Elevation Myocardial Infarction with a site in Russian Federation is open now. Recruiting first, the newest first:

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.

This study: 35 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in ST Elevation Myocardial Infarction with a site in Russian Federation, or all of them as a file.
02

Study summary

The primary goal

  • To assess the effect of atorvastatin in patients treated since the first 24-96 hours of the disease on the parameters of global and regional myocardial deformation in the infarcted area and the structural and functional properties of arteries at day 7, at 12, 24, 36 and 48 weeks of treatment;

The secondary goals. To evaluate the effect of treatment:

  • on the parameters of the global and regional myocardial deformation in the intact area on day 7, on 12, 24, 36 and 48 weeks of treatment;
  • on the parameters of the global and regional myocardial deformation depending on the degree of coronary blood flow restoration by thrombolysis in myocardial infarction (TIMI)
  • on systolic and diastolic left ventricular function in the presence of initial impairments, or absence of the negative dynamics of these parameters in case of normal baseline values;
  • on the clinical diagnostic criteria for the development or progression of heart failure;
  • the dynamics of the duration and extent of myocardial ischemia according to the daily ECG monitoring on day 7, at 12, 24, 36 and 48 weeks of treatment;
  • the appearance of new prognostically significant cardiac arrhythmias
  • on the pulse wave velocity
  • the thickness of the intima-media complex (IMT); 200 patients are planned to be include in a randomized, single-center, open, prospective, controlled clinical trial, the enrollment will be held at the Department of "Therapy" of Medical Institute of Penza State University.

Definition of the study group:

The patients with STEMI (myocardial infarction with ST-segment elevation) will be included in the study

  • Group 1 STEMI - 100 patients receiving atorvastatin 80 mg / day for 48 weeks;
  • Group 2 STEMI - 100 patients receiving atorvastatin 20 mg / day for 48 weeks Planned number of patients: Pre-Screening - 300 subjects; screening and randomization - 200 subjects.

Patients will be randomized by random number generation to include in the group 1 or 2. All included patients will be on the standard basis therapy of the coronary artery disease, according to the national recommendation.

Read the detailed description
  1. Hypotheses:
  1. Atorvastatin therapy directly results in improved deformation characteristics of hibernating myocardium due to its pleiotropic effects on endothelial dysfunction and atherosclerotic plaque stability, as well as stimulation of angiogenesis in ischemic zones of myocardium.
  2. Long-term atorvastatin therapy improves the morphofunctional properties of large arteries and decreases the severity of endothelial dysfunction in patients with a history of myocardial infarction.
  3. Atorvastatin causes an anti-ischemic effect, if used for a long time. 2.1. Primary objective To evaluate the effect of atorvastatin, when started between 24 and 96 hours after disease onset, on the parameters of global and regional myocardial deformation in the zone of infarction, as well as morphofunctional properties of arteries, on Day 7 and Weeks 12, 24, 36 and 48 of the treatment; 2.2. Secondary objectives. To evaluate:

    • the effect of treatment on the parameters of global and regional myocardial deformation in the zone of intact myocardium on Day 7 and Weeks 12, 24, 36 and 48 of the treatment;
    • the effect of treatment on the parameters of global and regional myocardial deformation depending on TIMI blood flow grade;
    • the effect of treatment on systolic and diastolic function of the left ventricle in patients with impaired left ventricular function at baseline, as well as the ability of this treatment to prevent deterioration of left ventricular function in patients with normal left ventricular function at baseline;
    • the effect of treatment on heart failure development and progression as assessed using the corresponding clinical diagnostic criteria;
    • the effect of treatment on duration and time course of myocardial ischemia using 24 hour ECG monitoring on Day 7 and Weeks 12, 24, 36 and 48 of treatment;
    • the effect of treatment on the appearance of new prognostically significant disorders of cardiac rhythm;
    • the effect of treatment on pulse wave velocity and cardio-ankle vascular index (CAVI);
    • the effect of treatment on intima-media thickness (IMT);
    • the effect of treatment on the results of automated quantitative vascular elasticity measurements, pulse wave and pulse pressure;
    • the effect of treatment on endothelial function using the reactive hyperemia test;
    • the effect of treatment on the time course of blood chemistry parameters (i.e., total cholesterol, HDL, LDL, triglycerides, creatinine, C-reactive protein (CRP), alanine transaminase (ALT), aspartate transaminase (AST) and creatinkinase (CK);
    • the safety of treatment;
    • the effect of treatment on patient's well-being and quality of life;
    • patient compliance with the therapy. 2.3. Scientific novelty of the study It is planned to study, for the first time, the effect of long-term aggressive statin therapy on the functional status of myocardium in the zone of ischemia, lesion and necrosis in patients with STEMI using the two-dimensional strain procedure.

It is planned, for the first time, to comprehensively study the effect of aggressive statin therapy on the status of vasculature, with measuring multiple parameters characterizing the morphofunctional status of elastic and muscular arteries in patients with documented coronary heart disease (CHD).

2.4. Clinical significance of study results. If the proposed hypotheses are confirmed after the primary endpoints described in Section 3 have been reached, new convincing evidence supporting the use of long-term aggressive treatment with Atorvastatin starting from the early stages of myocardial infarction will be obtained. Obviously, the clinical benefits will include the improved prognosis and decreased risk of repeated vascular events. Favorable effects of this therapy on the morphofunctional status of arterial vasculature will play an important role in the treatment of these patients. Positive results of this study can form the basis for planning and conducting larger studies on pleiotropic effects of Atorvastatin in patients with a history of myocardial infarction.

  1. Primary endpoints
  1. Statistically significant differences in spatial and velocity parameters of myocardial deformation in the zone of previous STEMI as compared to controls.
  2. Statistically significant differences in spatial and velocity parameters of myocardial deformation in the intact zone after STEMI as compared to controls.
  3. Statistically significant differences in intima-media thickness (IMT) according to echo tracking data as compared to controls.
  4. Statistically significant differences in carotid-femoral pulse wave velocity and CAVI as compared to controls.
  1. Planning and conducting the study. It is planned to include 200 patients in this randomized, open-label, single-center, prospective, controlled clinical study; these patients will be recruited at the Department of Therapy of the Penza State University Medical Institute.

4.1. Allocation to study groups:

Patients with STEMI will be included in this study:

Group 1: 100 patients with STEMI to receive atorvastatin at a dose of 80 mg per day for 48 weeks; Group 2: 100 patients with STEMI to receive atorvastatin at a dose of 20 mg per day for 48 weeks.

4.2. Planned number of patients: Prescreening - 300 patients; screening and randomization - 200 patients.

4.3. Study design. Patients will be randomized using sealed envelopes numbered with increasing serial numbers from 1 to 200; each envelope will contain information about patient inclusion into Group 1 or Group 2. Information about treatment schedule and dosing regimen will be provided separately.

4.3.1. Treatment regimen, dose titration strategy and combination treatment principles Patients meeting the inclusion criteria and not meeting the exclusion criteria will be included in the study.

Group A patients will start the treatment between 24 and 96 hours after the onset of STEMI:

  • Atorvastatin at a dose of 80 mg per day.

Group K patients will start the treatment between 24 and 96 hours after the onset of STEMI:

  • Atorvastatin at a dose of 20 mg per day.
03

Conditions studied

  • Myocardial Infarction

Browse trials for

Keywords

  • STEMI
  • myocardial strain
  • atorvastatin
04

In context

ST Elevation Myocardial Infarction Reclassified

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.

This study's enrollment of 200 is close to the median of 194 across 531 interventional studies indexed under ST Elevation Myocardial Infarction.

Browse ST Elevation Myocardial Infarction studies →

Lead sponsor

Penza State University is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Compared within ST Elevation Myocardial Infarction, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Myocardial Infarction. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
35 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed Form
  2. Patients having physical and mental ability to participate in the study
  3. Patients of both sexes aged 35 to 65 years
  4. Presence of documented ST-elevation myocardial infarction confirmed by , as well as troponin I and CK-MB levels.
  5. Presence of hemodynamically relevant stenosis of one artery (i.e., the infarct-related artery) confirmed by coronary angiography (CAG), with the occlusion of other arteries not exceeding 30%.

Exclusion criteria

Exclusion Criteria:

  1. A history of repeat or recurrent myocardial infarction;
  2. A history of chronic heart failure (CHF) III-IV by New-York Heart Association ();
  3. Presence of left ventricular hypertrophy confirmed by echocardiography;
  4. QRS complex exceeding 1.0;
  5. less than 40%;
  6. Presence of hemodynamically relevant stenosis exceeding 30% in several coronary arteries confirmed by CAG;
  7. Type 1 diabetes mellitus;
  8. Type 2 diabetes mellitus requiring pharmacotherapeutic correction with insulin;
  9. Any severe concurrent disease;
  10. A history of acute cerebrovascular accident (ACVA) within the 6 month period preceding the study;
  11. Active hepatic disease or liver enzyme elevation of unclear etiology more than 3 times higher than the ;
  12. Hepatic failure or elevation more than 1.5 times higher than the upper limit of normal;
  13. Uncontrolled arterial hypertension (AH), with systolic blood pressure (SBP) exceeding 180 mm Hg and diastolic blood pressure (DBP) exceeding 110 mm Hg;
  14. A history of heart rhythm and/or cardiac conduction disorder;
  15. Inborn and/or acquired heart defects;
  16. A history of aortic aneurysm;
  17. Current existence of severe anemia ( \< 100 g/L);
  18. Chronic renal disease ( \< 30 mL/min);
  19. Uncorrected thyroid dysfunction, with hyper- or hypothyroidism;
  20. Intolerance of statins;
  21. Alcohol abuse and drug use;
  22. Participation in other clinical studies within the last two months.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    Group A

    Group A patients will start atorvastatin at a dose of 80 mg/day between 24 and 96 hours after the onset of STEMI

    Drug: Atorvastatin

  • Active comparator
    Group K

    Group K patients will start atorvastatin at a dose of 20 mg/day between 24 and 96 hours after the onset of STEMI

    Drug: Atorvastatin

Interventions

07

What researchers measure

Primary outcomes

  1. Cardiovascular events

    Myocardial infarction, Unstable angina, Cardiac death

    Time frame: 2 years

Secondary outcomes

  1. Global myocardial strain in the zone of previous STEMI and in the intact zone after STEMI

    two-dimensional strain

    Time frame: 2 years

  2. Global myocardial strain rate in the zone of previous STEMI and in the intact zone after STEMI

    two-dimensional strain

    Time frame: 2 years

  3. Intima-media thickness of carotid artery

    echo-tracking

    Time frame: 2 years

  4. Carotid-femoral pulse wave velocity

    Applanation tonometry

    Time frame: 2 years

  5. Cardiac-ankle vascular index

    Volume sphygmography

    Time frame: 2 years

08

Study locations

1 site
  • Valentin Oleynikov
    Penza, 440026, Russian Federation
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2014 to primary completion in Dec 2019, 62 months.

Of 44 non-industry phase 4 interventional studies under ST Elevation Myocardial Infarction, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 74. This study's 62 months is above that.

Counting every sponsor, half of 49 studies reached it within 34 months; a quarter within 22 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2015
First posted
Oct 29, 2015
StartActual
Oct 2014
Primary completionActual
Dec 2019
CompletionActual
Feb 2020
Last update
Mar 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02590653
Lead sponsor
Penza State University
Responsible party
Sponsor
First posted
Oct 29, 2015
Start date
Oct 2014
Primary completion
Dec 2019
Completion
Feb 2020
Last update
Mar 24, 2020

Study contacts

Valentin Oleynikov, prof.
principal investigator · Head of Therapy Department

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion